Private equity firms continue their investment spree in the consumer health products sector, keeping it a hotbed for mergers and acquisitions, says private equity manager Slava Leykind. Investors' interest remains high because drug firms are selling some lines as they prioritize around top-selling brands.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?